Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2025)

Historic Deferred Taxes for Avalo Therapeutics (AVTX) over the last 9 years, with Q3 2025 value amounting to $10000.0.

  • Avalo Therapeutics' Deferred Taxes rose 17142.86% to $10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $148000.0, marking a year-over-year increase of 174444.44%. This contributed to the annual value of $114000.0 for FY2024, which is 71428.57% up from last year.
  • Per Avalo Therapeutics' latest filing, its Deferred Taxes stood at $10000.0 for Q3 2025, which was up 17142.86% from $16000.0 recorded in Q2 2025.
  • Avalo Therapeutics' Deferred Taxes' 5-year high stood at $114000.0 during Q4 2024, with a 5-year trough of -$62000.0 in Q4 2021.
  • In the last 5 years, Avalo Therapeutics' Deferred Taxes had a median value of $8000.0 in 2022 and averaged $8842.1.
  • The largest annual percentage gain for Avalo Therapeutics' Deferred Taxes in the last 5 years was 136666.67% (2024), contrasted with its biggest fall of 27500.0% (2024).
  • Avalo Therapeutics' Deferred Taxes (Quarter) stood at -$62000.0 in 2021, then surged by 112.9% to $8000.0 in 2022, then crashed by 212.5% to -$9000.0 in 2023, then soared by 1366.67% to $114000.0 in 2024, then crashed by 91.23% to $10000.0 in 2025.
  • Its Deferred Taxes was $10000.0 in Q3 2025, compared to $16000.0 in Q2 2025 and $8000.0 in Q1 2025.